Colorectal Cancer

Results could vary between having a net benefit or harm based on the balance between achieving screening in individuals who otherwise wouldn’t and using cell-free DNA blood tests in favor of more effective methods of screening for colorectal cancer (CRC).

Surgery for colorectal cancer has been both positive and challenging when using robotic-assisted surgeries.

Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.

Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.

The updated guidelines from the US Preventive Services Task Force (USPSTF) have led to an increase in screening for colorectal cancer (CRC) in individuals aged 45 to 49 years.

Increased time spent on discussing testing for colorectal cancer (CRC) was associated with patient satisfaction in older adults.

Patients with colorectal cancer (CRC) liver metastases had reduced risk of intrahepatic recurrence when using intraoperative contrast-enhanced ultrasounds.

Colorectal cancer (CRC) could be affected by various factors involved in sleep, including snoring.

A substantial overall survival (OS) disparity by race and ethnicity was found in patients with colorectal cancer (CRC), with socioeconomic status and tumor molecular features largely contributing to the difference in OS.

An update to the colonoscopy guidelines released by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy could have implications on how colonoscopies are measured in the future.

Patients who received radiotherapy without a recurrence of rectal cancer had significantly lower quality of life compared with patients who did not receive radiotherapy.

Educational principles implemented after 1998 may have led to lower mortality rates in patients with colorectal cancer (CRC) receiving care from doctors trained after that point.

Early-stage detection of colorectal cancer (CRC) could be achieved using a noninvasive multiomics liquid biopsy test, according to a recent study.

The new guidelines are another method of keeping a high-quality standard for colorectal cancer screening.

Cancer detection was slower to rebound after the COVID-19 pandemic compared with endoscopic activity, specifically in gastric cancers such as colorectal cancer.

Many patients could be at risk of colorectal cancer (CRC) without realizing as most patients don’t know if their immediate family has had CRC.

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted with patients.

Patients with symptoms of gastrointestinal (GI) problems and survivors of colon cancer were more likely to use oncology specialty care.

A simple, user-friendly decision-making model that used self-reported information was able to perform well in outpatient decision-making for patients with colorectal cancer (CRC).

Patients with colorectal liver metastases had local tumor progression when they had minimal ablative margin from intraprocedural contrast-enhanced computed tomography.

Tumor location, tumor size, and T stage associated with patients with rectal cancer who have inferior mesenteric artery lymph node metastases.

The Shield blood test developed by Guardant has been approved by the FDA as a primary screening option for colorectal cancer, providing a more convenient method of screening.

Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.

Overall and site-specific colorectal cancer (CRC) had a negative association with the usage of aspirin.

A nomogram model that included log odd of positive lymph node was effective in predicting prognosis of early-onset colorectal cancer (EOCRC).

Between 2016 and 2021, the percentage of screening colonoscopies performed by a family physician saw a decrease across the country.

In a recent study, novel genetic associations between obesity, colorectal cancer (CRC), and irritable bowel disease (IBD) were identified.

Patients who used adjuvant chemotherapy were found to have a higher survival rate after achieving complete pathological response.

Adult patients who have KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) can use adagrasib as a supplemental treatment.

Both preoperative pan-immune inflammation value (PIV) and monocyte to high-density lipoprotein ratio (MHR) were found to be independent risk factors when it came to the prognosis for colorectal cancer (CRC).